Synergistic Anti-Human Immunodeficiency Viral (HIV-1) Effect of the Immunomodulator Ampligen (Mismatched Double-Stranded RNA) with Inhibitors of Reverse Transcriptase and HIV-1 Regulatory Proteins

Abstract

The potent antiviral effect of double stranded RNA, such as the mismatched poly(l)·poly(C₁₂U) [Ampligen], 2′,3′-dideoxy-3′-fluorothymidine (FddThd) and antisense oligodeoxynucleotides (ODN) has been established in in vitro systems using cells infected with the human immunodeficiency virus type 1 (HIV-1). We report here that the immunomodulator poly(l)·poly(C₁₂U) interacts synergistically with (1) the reverse transcriptase inhibitor FddThd (FIC value: 0.43), (2) the modified (5′- and 3′-end capped thioates) antisense ODN-4 directed against the splice acceptor site of the HIV-1/tat gene (FIC value: 0.66) and (3) also with pyronin Y, a compound which prevents binding of HIV-1 Rev protein to the HIV-1 RRE element. These data suggest that combinations of poly(l)·poly(C₁₂U), a stimulator of the natural antiviral protection system of the cells, with compounds targeting HIV1-specific processes should be considered as candidate treatments of AIDS patients.

References

Baglioni

Minks

M.A.

, and Maroney

P.A.

(1978) Interferon action may be mediated by activation of a nuclease by pppA2′p5′A2′p5′A. Nature 273: 684–687.

Carter

W.A.

, and DeClercq

(1974) Viral infection and host defense. Science 186: 1172–1178.

Carter

W.A.

Strayer

D.R.

Brodsky

Lewin

Pellegrino

M.G.

Einck

Henriques

H.F.

Simon

G.L.

Parenti

D.M.

Scheib

R.G.

Schulof

R.S.

Montefiori

D.C.

Robinson

W.E.

Mitchell

W.M.

Volsky

D.J.

Paul

Paxton

Meyer

W.A.

III Karikó

Reichenbach

Suhadolnik

R.J.

, and Gillespie

D.H.

(1987) . Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet i: 1286–1292.

Chebath

Benech

Hovanessian

Galabru

, and Revel

(1987) . Four different forms of interferon-induced 2′,5′-oligo(A) synthetase identified by immunoblotting in human cells. J Biol Chem 262: 3852–3857.

Darzynkiewicz

Kapuscinski

Carter

S.P.

Schmid

F.A.

, and Melamed

M.R.

(1986) Cytostatic and cytotoxic properties of pyronin Y: Relation to mitochondrial localization of the dye and its interaction with RNA. Cancer Res 46: 5760–5766.

Daum

Engels

J.W.

Mag

Muth

Lucking

Schröder

H.C.

Matthes

, and Müller

W.E.G.

(1992) Antisense oligonucleotide: Inhibitor of splicing of mRNA of human immunodeficiency virus. Intervirology 33: 65–75.

Elion

G.B.

Singer

, and Hitchings

G.H.

(1954) . Antagonists of nucleic acid derivatives VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208: 477–488.

Engels

J.W.

Daum

Frauendorf

Lucking

Mag

Müller

W.E.G.

Muth

, and Rosmanitz

(1991) Backbone modified oligodeoxynucleotides: Stereoselective synthesis of methylphosphonates and HIV inhibitory capacity of phosphorothioates. Nucleic Acids Res 24: 83–86.

Goodchild

Agrawal

Civeira

M.P.

Sarin

P.S.

Sun

, and Zamechnik

P.C.

(1988) Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci, USA 85: 5507–5511.

10.

D.D.

Hartshorn

K.L.

Rota

T.R.

Andrews

C.A.

Kaplan

J.C.

Schooley

R.T.

, and Hirsch

M.S.

(1985) Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet i: 602–604.

11.

Hubbell

H.R.

Sheetz

P.C.

logal

S.S.

Brodsky

Kariko

S.-W.

Suhadolnik

R.J.

, and Sobol

R.W.

(1991) Heterogeneous nuclear RNA from hairy cell leukemia patients activates 2′,5′-oligoadenylate synthetase. Anticancer Res 11: 1927–1932.

12.

Ilson

D.H.

Torrence

P.F.

, and Vilcek

(1986) Two molecular weight forms of human 2′,5′-oligoadenylate synthetase have different activation requirements. J Interferon Res 6: 5–12.

13.

Jamison

J.M.

Krabill

Allen

K.A.

Stuart

S.H.

, and Tsai

C.C.

(1990) . RNA-intercalating agent interactions: in vitro antiviral activity studies. Antiviral Chem Chemother 1: 333–347.

14.

Krown

S.E.

Friden

G.B.

Khansur

Davies

M.E.

Oettegen

H.F.

, and Field

A.K.

(1983) Phase I trial with the interferon inducer poly l:C/L-lysine (Poly ICL). J Interferon Res 3: 281–290.

15.

Lammers

Gross

Mayr

, and Collins

(1988) Alternative mechanisms for gene activation induced by poly(rl)·poly(rC) and Newcastle disease virus. Eur J Biochem 178: 93–99.

16.

Matthes

Lehmann

Janta-Lipinski

M.v.

, and Scholz

(1989) Inhibition of HIV-replication by 3′-fluoro-modified nucleosides with low cytotoxicity. Biochem Biophys Res Commun 165: 488–495.

17.

Mirabelli

C.K.

Bennett

C.F.

Anderson

, and Crooke

S.T.

(1991) In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Res 6: 647–661.

18.

Mitchell

Montefiori

D.C.

Robinson

W.F.

Strayer

D.R.

, and Carter

W.A.

(1987) Mismatched double-stranded RNA (ampligen) reduced concentration of zidovudine (azidothymidine) required for in vitro inhibition of human immunodeficiency virus. Lancet i: 890–892.

19.

Mitsuya

, and Broder

(1987) Strategies for antiretroviral therapy in AIDS. Nature 325: 773–778.

20.

Montefiori

D.C.

, and Mitchell

W.M.

(1987) Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci, USA 84: 2985–2989.

21.

Montefiori

D.C.

Sobol

R.W.

S.W.

Reichenbach

N.L.

Suhadolnik

R.J.

Charubala

Pfleiderer

Modliszewski

Robinson

W.E.

, and Mitchell

W.M.

(1989) Phosphorothioate and cordycepin analogues of 2′,5′-oligoadenylate: Inhibition of human immunodeficiency virus type 1 reverse transcriptase and infection in vitro. Proc Natl Acad Sci, USA 86: 7191–7194.

22.

Müller

W.E.G.

, and Zahn

R.K.

(1979) Metabolism of 1-β-D-arabinofuranosyluracil in mouse L5178y cells. Cancer Res 39: 1102–1107.

23.

Müller

W.E.G.

Sarin

P.S.

Sun

Rossol

Voth

Rottmann

Hess

zum Büschenfelde

K.-H. Meyer

, and Schröder

H.C.

(1988) Dual biological activity of apurinic acid on human lymphocytes. Antiviral Res 9: 191–204.

24.

Müller

W.E.G.

Weiler

B.E.

Charubala

Pfleiderer

Leserman

Sobol

R.W.

Suhadolnik

R.J.

, and Schröder

H.C.

(1991) Cordycepin analogues of 2′,5′-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochemistry 30: 2027–2033.

25.

Nilsen

T.W.

Wood

D.L.

, and Baglioni

(1982) Presence of 2′,5′-oligo(A) and of enzymes that synthesize, bind, and degrade 2′,5′-oligo(A) in HeLa cell nuclei. J Biol Chem 257: 1602–1605.

26.

Phillips

, and Warren

(1976) Activity of sulfamethoxazole and trimethoprim against Bacteroides fragilis. Antimicrob Agents Chemother 9: 736–740.

27.

Ratner

Haseltine

Patarca

Livak

K.J.

Stracich

Josephs

S.F.

Doran

E.R.

Rafalski

J.A.

Whitehoin

E.A.

Baumeister

Ivanoff

Petteway

S.R.

Pearson

M.L.

Lautenberger

J.A.

Papas

T.S.

Ghrayeb

Chang

N.T.

Gallo

R.C.

, and Wong-Staal

(1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284.

28.

Sachs

(1984) Angewandte Statistik. Springer-Verlag, Berlin.

29.

Sarin

P.S.

Sun

Thornton

, and Müller

W.E.G.

(1987) Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by Avarol and Avarone. J Natl Cancer Inst 78: 663–666.

30.

Schröder

H.C.

Wenger

Kuchino

, and Müller

W.E.G.

(1989) Modulation of nuclear matrix-associated (2′-5′)oligoadenylate metabolism and ribonuclease L activity in H9 cells by human immunodeficiency virus. J Biol Chem 264: 5669–5673.

31.

Schröder

H.C.

Ugarkovic

Merz

Kuchino

Okamoto

, and Müller

W.E.G.

(1990a) Protection of HeLa-T4⁺ cells against human immunodeficiency virus (HIV) infection after stable transfection with HIV LTR-2′,5′-oligoadenylate synthetase hybrid gene. FASEB J 4: 3124–3130.

32.

Schröder

H.C.

Ugarkovic

Wenger

Okamoto

, and Müller

W.E.G.

(1990b) Binding of Tat protein to TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2′-5′)oligoadenylate synthetase. AIDS Res Hum Retrovir 6: 659–672.

33.

Schröder

H.C.

Suhadolnik

R.J.

Pfleiderer

Charubala

, and Müller

W.E.G.

(1992) (2′-5′)Oligoadenylate and intracellular immunity against retrovirus infection. Int J Biochem 24: 55–63.

34.

Schröder

H.C.

Ushijima

Bek

Merz

Pfeifer

, and Müller

W.E.G.

(1993) Inhibition of formation of Rev-RRE complex by Pyronin Y. Antiviral Chem Chemother., in press.

35.

Scudiero

D.A.

Shoemaker

R.H.

Pauli

K.D.

Monks

Tierney

Nofziger

T.H.

Currens

M.J.

Seniff

, and Boyd

M.R.

(1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 40: 4827–4833.

36.

Silverman

R.H.

Jung

D.D.

Nolan-Sorden

N.L.

Dieffenbach

C.W.

Kedar

V.P.

, and SenGupta

D.N.

(1988) Purification and analysis of murine 2-5A-dependent RNase. J Biol Chem 263: 7336–7341.

37.

Sommadossi

J.P.

, and Carlisle

(1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanosine for normal human hematopoietic progenitor cells. Antimicrob Agents Chemother 31: 452–454.

38.

Strayer

D.R.

Watson

Carter

W.A.

, and Brodsky

(1986) Antiproliferative effect of mismatched double-stranded RNA on fresh human tumor cells analyzed in a clonogenic assay. J Interferon Res 6: 373–379.

39.

Strayer

D.R.

Carter

W.A.

Pequignot

Topolsky

Brodsky

Suhadolnik

R.J.

Reichenbach

Paul

Einck

Hubbell

E.R.

Pinto

Strauss

, and Gillespie

(1991) Activity of synthetic dsRNA - Ampligen- in HIV disease. Clinical Biotechnology 3: 169–175.

40.

Suhadolnik

R.J.

Lebleu

Pfleiderer

Charubala

Montefiori

D.C.

Mitchell

W.M.

Sobol

R.W.

S.W.

Kariko

, and Reichenbach

N.L.

(1989) Phosphorothioate analogs of 2′-5′A: Activation/inhibition of RNaseL and inhibition of HIV-1 reverse transcriptase. Nucleoside Nucleotide 8: 987–990.